Estrogen replacement therapy modulates spontaneous GH secretion but does not affect GH-RH-induced GH response and low T3 syndrome in women with hypothalamic amenorrhea associated to weight-loss.
Severe dieting and negative energy balance usually lead to the occurrence of amenorrhea together with several endocrine disturbances such as the "low T3 syndrome" and an abnormal GH secretion. To evaluate whether estrogen replacement therapy (ERT) affects thyroid hormones and GH secretion, two groups of patients affected by weight-loss-related amenorrhea and with low plasma T3 levels were treated with two different schedules of ERT using 50 or 100 micrograms estradiol transdermal patches twice a week (Dermestril, Rottapharm, Monza, Italy). Before and after 5 weeks of therapy in each patient thyroid hormones, spontaneous GH secretion and GH-RH-induced GH release were evaluated. After ERT, plasma GH and IGF-1 levels increased in both groups and a consistent change in GH spontaneous release was observed. Conversely the low T3 plasma levels and GH-RH-induced GH response were not modified by ERT. Our present data suggest that in amenorrhea related to weight-loss, hormonal abnormalities are only in part dependent from the hypoestrogenic condition.
Genazzani
A D
AD
Clinica Ostetrica Ginecologica, University of Modena, Italy.
Gamba
O
O
Petraglia
F
F
D000279:Administration, Cutaneous; D000328:Adult; D000568:Amenorrhea / Q000209:etiology / Q000503:physiopathology*; D015992:Body Mass Index; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D007031:Hypothalamus / Q000503:physiopathology; D010507:Periodicity; D014284:Triiodothyronine / Q000172:deficiency*; D015431:Weight Loss
D014284:Triiodothyronine; D019382:Human Growth Hormone; D004958:Estradiol; D013007:Growth Hormone-Releasing Hormone